Design, synthesis and molecular modelling of 1-amidinopiperidine thrombin inhibitors

Pharmazie

Volumn 62, Issue 4, 2007, Pages 243-254

  Smolnikar, I ^a   Perdih, A ^a   Stegnar, M ^b   Prezelj A ^c   Solmajer T ^a   Urleb, U ^a,c   Obreza, Aleš ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c Lek dd   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOPIPERIDINE; ARGATROBAN; METHYL 3 [[1 (1 AZEPANYLCARBONYL) 2 (TERT BUTOXYCARBONYL)HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 3 [[1 (1 AZEPANYLCARBONYL)HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 3 [[1 (1 PIPERIDINYLCARBONYL)HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 3 [[1 (4 MORPHOLINYLCARBONYL)HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 3 [[1 [(4 METHYL 1 PIPERIDINYL) CARBONYL]HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 3 [[2 (TERT BUTOXYCARBONYL) 1 (1 PIPERIDINYLCARBONYL)HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 3 [[2 (TERT BUTOXYCARBONYL) 1 (4 MORPHOLINYLCARBONYL)HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 3 [[2 (TERT BUTOXYCARBONYL) 1 (CYCLOHEPTYLAMINO)CARBONYL]HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 3 [[2 (TERT BUTOXYCARBONYL) 1 [(4 METHYL 1 PIPERIDINYL)CARBONYL]HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 3 [[2 (TERT BUTOXYCARBONYL) 1 [(CYCLOPENTYLAMINO)CARBONYL]HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 3 [[2 (TERT BUTOXYCARBONYL) 1 [[CYCLOHEXYL(METHYL)AMINO]CARBONYL]HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 4 [[1 (1 AZEPANYLCARBONYL) 2 (TERT BUTOXYCARBONYL)HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 4 [[1 (1 AZEPANYLCARBONYL)HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 4 [[1 (1 PIPERIDINYLCARBONYL)HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 4 [[1 [(4 METHYL 1 PIPERIDINYL)CARBONYL]HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 4 [[2 (TERT BUTOXYCARBONYL) 1 (1 PIPERIDINYLCARBONYL)HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 4 [[2 (TERT BUTOXYCARBONYL) 1 (4 MORPHOLINYLCARBONYL)HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 4 [[2 (TERT BUTOXYCARBONYL) 1 [(4 METHYL 1 PIPERIDINYL)CARBONYL]HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 4 [[2 (TERT BUTOXYCARBONYL) 1 [(CYCLOHEPTYLAMINO)CARBONYL]HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 4 [[2 (TERT BUTOXYCARBONYL) 1 [(CYCLOPENTYLAMINO)CARBONYL]HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; METHYL 4 [[2 (TERT BUTOXYCARBONYL) 1 [[CYCLOHEXYL(METHYL)AMINO]CARBONYL]HYDRAZINO]METHYL] 1 PIPERIDINECARBOXYLIC ACID; PARACETAMOL; TERT BUTYL 2 (3 PIPERIDINYLMETHYL) 1 HYDRAZINECARBOXYLIC ACID; TERT BUTYL 2 (3 PYRIDINYLMETHYLIDENE) 1 HYDRAZINECARBOXYLIC ACID; TERT BUTYL 2 (4 PIPERIDINYLMETHYL) 1 HYDRAZINECARBOXYLIC ACID; TERT BUTYL 2 (4 PYRIDINYLMETHYLIDENE) 1 HYDRAZINECARBOXYLIC ACID; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG DESIGN; HUMANS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PARTIAL THROMBOPLASTIN TIME; PIPERIDINES; PROTHROMBIN TIME; SPECTROPHOTOMETRY, INFRARED; THROMBIN; THROMBIN TIME; TRYPSIN INHIBITORS;

EID: 34247159532     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2007.4.6547     Document Type: Article

References (17)

1. Banner DW, Hadvary P (1991) Crystallographie analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors. J Biol Chem 266: 20085-20093.
2. -/alpha-(3-methyl-1,2,3,4- tetrahydro-8- quinolinesulphonyl)-L- arginyl]-2-piperidine carboxylic acid (MQPA) to human alpha-thrombin. X-ray crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP- thrombin and MQPA-thrombin Eur J Biochem 193: 175-182.
3. Brandt RB, Laux JE, Yates SW (1987) Calculation of inhibitor Ki and inhibitor type from the concentration of inhibitor for 50% inhibition for Michaelis-Menten enzymes. Biochem Med Metab Biol 37: 344-349.
4. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 23: 3099-3108.
5. Gresele P, Agnelli G (2002) Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci 23: 25-32.
6. Hilpert K, Ackermann J, Gast A, Gubernator K, Hadvary P, Labler L, Müller K, Schmid G, Tschopp TB, van de Waterbeemd H (1994) Design and sythesis of potent and highly selective thrombin inhibitors. J Med Chem 37: 3889-3901.
7. Isaacs RCA, Cutrona KJ, Newton CL, Sanderson PEJ, Solinsky MG, Baskin EP, Chen IW, Cooper CM, Cook JJ, Gardell SJ, Lewis SD, Lucas RJ, Lyle EA, Lynch JJ, Naylor-Olsen AM, Stranieri MT, Vastag K, Vacca JP (1998) C6 Modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption Bioorg Med Chem Lett 8: 1719-1724.
8. Mlinšek G, Novic M, Kotnik M, Šolmajer T (2004) Prediction of enzyme binding: human thrombin inhibition study by quantum chemical and artificial intelligence methods based on X-ray structures. J Chem Inf Comp Sci 5: 1872-1882.
9. Obreza A, Stegnar M, Urleb U (2004a) Novel non-covalent azaphenylalanine thrombin inhibitors with an aminomethyl or amino group at the P1 position. Pharmazie 59: 659-666.
10. Obreza A, Stegnar M, Trampuš-Bakija A, Preželj A, Urleb U (2004b) Synthesis and in vitro evaluation of new azaphenylalanine derivatives as serine protease inhibitors. Pharmazie 59: 739-743.
11. Rarey M, Kramer B, Lengauer T, Klebe G Fast A (1996) Flexible docking method using an incremental construction algorithm. J Mol Biol 261: 470-489.
12. Rewinkel JBM, Adang AEP (1999) Strategies and progress towards the ideal orally active thrombin inhibitor. Curr Pharm Des 5: 1043-1075.
13. Sanderson PEJ, Cutrona KJ, Dorsey BD, Dyer DL, McDonough CM, Naylor-Olsen AM, Chen IW, Chen ZG, Cook JJ, Gardell SJ, Krueger JA, Lewis SD, Lin JH, Lucas BJ, Lyle EA, Lynch JJ, Stranieri MT, Vastag K, Shafer JA, Vacca JP (1998) L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitors. Bioorg Med Chem Lett 8: 817-822.
14. Steinmetzer T, Hauptmann J, Stürzebecher J (2001) Advances in the development of thrombin inhibitors. Exp Opin Invest Drugs 10: 845-864.
15. Zega A, Mlinšek G, Šepic P, Golič Grdadolnik S, Šolmajer T, Tschopp TB, Steiner B, Kikelj D, Urleb U (2001a) Design and strucure-activity relationship of thrombin inhibitors with an azaphenylalanine scaffold: potency and selectivity enhancements via P2 optimization. Bioorg Med Chem 9: 2745-2756.
16. Zega A, Trampuš-Bakija A, Fortuna M, Stegnar M, Tschopp TB, Steiner B, Urleb U (2001b) Novel thrombin inhibitors with azaphenylalanine scaffold. Pharmazie 56, 683-685.
17. Zega A, Mlinšek G, Šolmajer T, Brakija-Trampuš A, Stegnar S, Urleb U (2004) Thrombin inhibitors built on an azaphenylalanine scaffold. Bioorg Med Chem Lett 14, 1563-1567.